Wells Fargo & Company Halozyme Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 703,941 shares of HALO stock, worth $34.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

703,941

Previous 646,255 8.93%

Holding current value

$34.2 Million

Previous $33.8 Million 19.02%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $2.96 Million - $3.72 Million	57,686 Added 8.93%	703,941 $40.3 Million
Q2 2024 Aug 13, 2024	BUY	$37.81 - $52.4 $339,495 - $470,499	8,979 Added 1.41%	646,255 $33.8 Million
Q1 2024 May 10, 2024	SELL	$33.68 - $41.95 $653,661 - $814,165	-19,408 Reduced 2.96%	637,276 $25.9 Million
Q4 2023 Feb 09, 2024	SELL	$33.32 - $42.1 $604,924 - $764,325	-18,155 Reduced 2.69%	656,684 $24.3 Million
Q3 2023 Nov 13, 2023	SELL	$36.46 - $44.03 $842,882 - $1.02 Million	-23,118 Reduced 3.31%	674,839 $25.8 Million
Q2 2023 Aug 15, 2023	BUY	$30.28 - $38.74 $2.26 Million - $2.89 Million	74,621 Added 11.97%	697,957 $25.2 Million
Q1 2023 May 12, 2023	BUY	$32.86 - $55.7 $5.3 Million - $8.99 Million	161,334 Added 34.92%	623,336 $23.8 Million
Q4 2022 Feb 13, 2023	SELL	$40.06 - $59.44 $6.76 Million - $10 Million	-168,835 Reduced 26.76%	462,002 $26.3 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $18 Million - $24.2 Million	467,998 Added 287.4%	630,837 $24.9 Million
Q2 2022 Aug 12, 2022	SELL	$37.35 - $48.3 $10.3 Million - $13.3 Million	-276,326 Reduced 62.92%	162,839 $7.17 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $1.34 Million - $1.73 Million	-42,070 Reduced 8.74%	439,165 $17.5 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $27.7 Million - $35.5 Million	-871,292 Reduced 64.42%	481,235 $19.4 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $8.07 Million - $9.74 Million	209,853 Added 18.37%	1,352,527 $55 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $1.6 Million - $2.11 Million	41,104 Added 3.73%	1,142,674 $51.9 Million
Q1 2021 May 13, 2021	SELL	$39.51 - $51.45 $2.04 Million - $2.66 Million	-51,703 Reduced 4.48%	1,101,570 $45.9 Million
Q4 2020 Feb 09, 2021	SELL	$25.81 - $43.62 $3.7 Million - $6.25 Million	-143,304 Reduced 11.05%	1,153,273 $49.3 Million
Q3 2020 Nov 05, 2020	BUY	$25.74 - $29.63 $2.27 Million - $2.61 Million	88,021 Added 7.28%	1,296,577 $34.1 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $1.61 Million - $2.65 Million	98,838 Added 8.91%	1,208,556 $32.4 Million
Q1 2020 May 14, 2020	BUY	$13.9 - $21.83 $15.4 Million - $24.2 Million	1,109,718 New	1,109,718 $20 Million

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.77B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Halozyme Therapeutics, Inc. Transaction History